BGM Group Ltd.·Healthcare

BGM Group Ltd. (NASDAQ: BGM - Get Free Report) was the target of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 65,241 shares, a decline of 13.0% from the February 12th total of 74,988 shares. Currently, 0.2% of the shares of the company are

CHENGDU, China, Feb. 26, 2026 (GLOBE NEWSWIRE) -- BGM Group Ltd. (NASDAQ: BGM) (the “Company” or “BGM”) announced on February 24, 2026, that it has received a notification (the “Notification”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) regarding its non-compliance with the Nasdaq Listing Rule 5250 (c)(1) as a result of the Company's failure to file its Annual Report on Form 20-F for the fiscal year ended September 30, 2025 (the “Form 20-F”) in a timely manner.

Shares of BGM Group Ltd. (NASDAQ: BGM - Get Free Report) fell 1% during mid-day trading on Friday. The stock traded as low as $1.02 and last traded at $1.04. 32,715 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 111,259 shares. The stock had previously closed at

Rhythm Pharmaceuticals (NASDAQ: RYTM - Get Free Report) and BGM Group (NASDAQ: BGM - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a summary of current
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.
Healthcare
Drug Manufacturers - Specialty & Generic
298
2003-01-24
1.93